#Sweden #Stockholm #Drug Discovery #Salipro Biotech #Salipro technology

Salipro Biotech Strengthens Its Intellectual Property with New Patents

Salipro Biotech AB, a pioneering biotechnology firm based in Sweden, has made significant strides in expanding its global intellectual property (IP) portfolio. The company recently announced the granting of patents in both Singapore and Australia, which protect its innovative Salipro® platform technology. This technology aims to facilitate drug discovery targeting notoriously challenging drug targets—specifically, membrane proteins.

Understanding the Salipro® Platform

The Salipro® technology offers a novel approach to the isolation and purification of native membrane proteins, a critical class of targets used in therapeutic drug development. Often, these proteins can be unstable in their natural form, which complicates their study and manipulation. Salipro's methodology addresses this issue, allowing for much-needed advancements in discovering new therapeutics.

The issued patents, known as "Production of Salipro® Particles" (Australian Patent No. 2020257991; Singapore Patent No. 11202111111U), highlight processes integral to the Salipro® platform. This achievement is pivotal in establishing Salipro Biotech's position as a key player in drug discovery, particularly for difficult-to-target proteins such as G protein-coupled receptors (GPCRs), ion channels, and transporters.

CEO Insights: A New Chapter in Global IP Strategy

Jens Frauenfeld, CEO of Salipro Biotech, expressed enthusiasm regarding the recent patent grants, marking them as a considerable advancement in their global IP strategy. He emphasized the importance of building a robust portfolio that not only safeguards their unique technology but also supports their mission to tackle unmet medical needs utilizing the Salipro® platform.

"This achievement is crucial for our long-term growth and solidifies our IP position across essential markets, complementing our foundational patents already granted in major jurisdictions like the U.S., EU, China, and Japan," said Frauenfeld.

The strategic safeguarding of such technology is vital for positions within the competitive biotechnology landscape, especially when it comes to forming collaborations with pharmaceutical companies.

Strategic Collaborations and Future Directions

Salipro Biotech is keenly focused on nurturing collaborations and licensing agreements with leading pharmaceutical enterprises. Peter Jahnmatz, the Business Development Director at Salipro Biotech, remarked that these new patents will enhance the company’s value proposition for partners. By strengthening their IP profile, Salipro aims to expedite the development of next-generation therapeutics tailored to previously insurmountable drug targets.

The successful navigation of the biotechnology industry's intricate terrain requires not just innovative technologies but also strategic partnerships. Salipro Biotech actively pursues these opportunities, showing its commitment to advancing drug discovery through fruitful collaborations and shared expertise.

About Salipro Biotech AB

Established in Stockholm, Sweden, Salipro Biotech AB specializes in unlocking difficult drug targets to accelerate the development of next-generation therapeutics. The company holds a comprehensive IP portfolio encompassing its proprietary Salipro® platform technology, designed specifically for stabilizing membrane proteins.

As the landscape of drug discovery evolves, Salipro Biotech stands at the forefront, helping to reshape the way pharmaceutical companies engage in therapeutic development. By combining an array of research collaborations with prominent pharma and biotech firms, the organization accelerates the pace at which novel drugs can reach the market.

For more detailed inquiries or to learn about ongoing projects, interested parties can visit Salipro Biotech's website or connect on platforms like LinkedIn and Twitter.